In recent years，the incidence of prostate cancer（PCa）has gradually increased，positron emission tomography（PET）and single photon emission computed tomography（SPECT）technology have been rapidly popularized，the research and development of radiopharmaceuticals for PCa diagnosis has been developed rapidly. The development of novel radiopharmaceuticals for diagnosing prostate cancer（PCa）primarily focuses on targeting prostate-specific membrane antigens（PSMA）through drug labeling，including specific antibodies and small molecule inhibitors. At the same time， other targets related to prostate cancer have been actively explored，and good progress has been made in clinical practice. This article reviewed the recent development of radiopharmaceuticals for the diagnosis of specific molecular targets of prostate cancer.